Kiniksa Pharmaceuticals Interna (KNSA) Stock Analysis
Range Bound setup
Healthcare · Drug Manufacturers - Specialty & Generic
Sell if holding. At $53.34, A.R:R 0.2:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Thin upside margin: 3.6%; Leverage penalty (D/E 1.5): -0.5.
Kiniksa Pharmaceuticals is a commercial-stage biopharmaceutical company with ARCALYST (rilonacept) approved in the US, EU, and Japan for dystrophic epidermolysis bullosa and other IL-1-mediated conditions. Revenue comes almost entirely from ARCALYST US sales ($730.3M cumulative... Read more
Sell if holding. At $53.34, A.R:R 0.2:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Thin upside margin: 3.6%; Leverage penalty (D/E 1.5): -0.5. Chart setup: RSI 51 mid-range, Bollinger mid-band. Score 5.8/10, moderate confidence.
Passes 6/8 gates (clean insider activity, no SEC red flags, news events none recent, earnings proximity 70d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio. Suitability: aggressive.
Recent Developments — Kiniksa Pharmaceuticals Interna
Latest news
- Kiniksa Pharmaceuticals International (KNSA) Reports Q1 2026 Numbers - AlphaStreet — AlphaStreet neutral
- Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Shares Gap Up After Better-Than-Expected Earnings - MarketBeat — MarketBeat positive
- KNSA Expects Higher Revenue Projections for ARCALYST in 2026 - GuruFocus — GuruFocus positive
- KNSA Earnings: Kiniksa Pharmaceuticals Stock Surges on Strong Q1 Beats - TipRanks — TipRanks positive
- Kiniksa Pharmaceuticals International, plc (KNSA) Tops Q1 Earnings and Revenue Estimates - Yahoo Finance — Yahoo Finance positive
Generated 2026-05-20T21:06:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
2 floor-breakers·1 ceiling hit
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. At $53.34, A.R:R 0.2:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Thin upside margin: 3.6%; Leverage penalty (D/E 1.5): -0.5. Chart setup: RSI 51 mid-range, Bollinger mid-band. Prior stop was $49.61. Score 5.8/10, moderate confidence.
Take-profit target: $55.24 (+3.6% upside). Prior stop was $49.61. Stop-loss: $49.61.
Thin upside margin: 3.6%; Leverage penalty (D/E 1.5): -0.5; Consecutive earnings misses (3).
Kiniksa Pharmaceuticals Interna trades at a P/E of 58.9 (forward 30.5). TrendMatrix value score: 4.9/10. Verdict: Sell.
14 analysts cover KNSA with a consensus score of 4.3/5. Average price target: $64.
What does Kiniksa Pharmaceuticals Interna do?Kiniksa Pharmaceuticals is a commercial-stage biopharmaceutical company with ARCALYST (rilonacept) approved in the US,...
Kiniksa Pharmaceuticals is a commercial-stage biopharmaceutical company with ARCALYST (rilonacept) approved in the US, EU, and Japan for dystrophic epidermolysis bullosa and other IL-1-mediated conditions. Revenue comes almost entirely from ARCALYST US sales ($730.3M cumulative since launch); the pipeline includes KPL-387 (Phase 2/3 for recurrent pericarditis) and KPL-1161 (preclinical).